Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05844137
Other study ID # Pro00113239
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 18, 2023
Est. completion date January 29, 2024

Study information

Verified date March 2024
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this pilot study is to assess the feasibility and acceptability of an intervention for improved detection and evidence-based care of NAFLD in Latinx and Black patients with type 2 diabetes (T2D) in Duke University Healthcare system (DUHS). We will enroll 10-15 Latinx and 10-15 Black patients with T2D and NAFLD, based on having mildly elevated liver enzymes (ALT >/= 40 IU/mL in males, ALT >/= 31 IU/mL in females) and exclusion of other liver diseases (e.g., viral hepatitis, alcohol abuse). Intervention content will include: 1) NAFLD education; 2)diet/lifestyle support; 3) T2D medication management; and 4) clinically-indicated liver testing and care. Intervention feasibility will be evaluated by examining recruitment rates, retention rates, and study visit completion rates. Acceptability will be assessed by survey and through qualitative interviews. The project objectives and intervention are minimal risk. The expected risks will not exceed those of usual care.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date January 29, 2024
Est. primary completion date January 29, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - People who identify as either: Latino/Latina/Hispanic ethnicity and/or Black or African American race - People with type 2 diabetes (T2D), as defined by ICD-10 codes E11.xx. - Patients with elevated serum alanine aminotransferase (ALT) within Duke University Healthcare System (DUHS). Elevated ALT will be defined as having at least two ALT =40 IU/mL in males or =31 IU/mL in females in the preceding 12 months Exclusion Criteria: - People with hepatitis B or C infection - People with known alcohol overuse - People with current use of chemotherapy or other drugs known to affect liver function - People who have not been seen by a DUHS Primary Care Physician (PCP) or Endocrinologist in the preceding year.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
NAFLD Education
NAFLD Education
diet/lifestyle support
diet/lifestyle support
Drug:
T2D medication management
T2D medication management
Diagnostic Test:
clinically-indicated liver testing and care
clinically-indicated liver testing and care

Locations

Country Name City State
United States Duke University Healthcare System Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility as measured by recruitment rate We will assess recruitment rates: Patients eligible and sent letter of message / Patients enrolled 3months
Primary Feasibility as measured by retention rate We will assess retention rates: Patients enrolled / Patients completing study 3months
Primary Feasibility as measured by visit completion rate We will assess visit completion rates: Total study visits completed / Total study visits scheduled 3months
Primary Feasibility of system-level NAFLD detection approach Patients who met criteria for NAFLD after chart review / total number of potentially-eligible patients based on our EHR criteria. We will deem this approach feasible if detection rates are >70%. Baseline
Primary Acceptability of intervention by participants We will calculate the mean and standard deviation of the Treatment Acceptability and Preferences (TAP);Minimum value = 0; Maximum value = 4; Higher score is a better outcome (ie more acceptable). We will define acceptable score as mean TAP = 3. 3months
Secondary Change in Self-Efficacy measured by the Managing Chronic Diseases (SEMCD) score The SEMCD is a 6-item scale with a minimum value = 1; Maximum value = 10; Higher score is a better outcome (ie greater self-efficacy) Maximum value = 60, Higher score is a better outcome (ie greater self-efficacy).
Will be measured by a change of >/=1.
Baseline, 3months
Secondary Change in Self-Efficacy measured by the Modified Health care Climate Questionnaire (HCCQ) The HCCQ is a 5-item scale with a minimum value = 1; Maximum value = 5; Higher score is a better outcome (ie greater self-management)
Will be measured by a change of >/=1 as being clinically significant.
Baseline, 3months
Secondary Change in Quality of Living as measured by the SF-12 The SF-12 is a 5-item scale with a minimum value = 0; Maximum value = 100; Higher score is a better outcome (ie greater quality of life)
Will be measured by a change of >/=10 as being clinically significant.
Baseline, 3months
Secondary Change in mean hemoglobin A1c (HbA1c) Change of >/= 0.5% will be deemed clinically significant Baseline, 3months
Secondary Change in mean alanine aminotransferase (ALT) level Change of >/= 5 IU/mL will be deemed clinically significant. Baseline, 3months
Secondary Change in medication adherence Change as measured by the Voils Non-adherence measure. Minimum value = 0; maximum value = 5. Higher score is worse outcome (ie more non-adherence). Will be measured by change of >/= 1. Baseline, 3months
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A